Chronic Lymphocytic Leukemia

This is the first trial to show that a measurable residual disease (MRD)–guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of progression-free survival and overall survival.

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

The acceptance comes after results from TRANSCEND CLL 004, which is the first trial to demonstrate clinical benefit with a CAR T cell therapy in patients who were previously treated for CLL or SLL.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

A low dose of the combination treatment inhibited AML cell cycle and increased apoptosis.

Lisaftoclax is a novel, oral, small-molecule, BCL-2 selective inhibitor being evaluated for treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.

Irreversible Bruton tyrosine kinase inhibitor produces positive results in patients with relapsed/refractory marginal zone lymphoma.

Pirtobrutinib is a non–covalent (reversible) BTK inhibitor, demonstrating a 73.3% overall response rate with a median follow-up of 19.4 months among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In-person visits to receive oral therapy, outpatient infusions, and inpatient infusion for the treatment of hematologic neoplasms declined in the early months of the COVID-19 pandemic, while telemedicine use increased slightly in the same period but remained low overall.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.

Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.

CRISPR technology has also been successful in treating a pediatric patient with T-cell acute lymphoblastic leukemia, showing feasibility of its use for cancer immunotherapy.

At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, opens a discussion surrounding chronic lymphocytic leukemia (CLL).

Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.

Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Phase 1 clinical trial data show the drug to be active with evidence of clinically meaningful responses and a manageable safety profile.

Although patients with Richter syndrome often experience poor outcomes, there are many new treatment strategies that have demonstrated a durable response.

Zanubrutinib expressed better cardiac safety measures, higher progression-free survival, and lower discontinuation rates in the ALPINE trial compared with compared ibrutinib.

Investigators believe the findings can refine predictions, after independent evaluation, by identifying different modes of genetic alteration.

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

Opportunities for further optimization of CML management remain.

Zanubrutinib (Brukinsa) is a small molecule Bruton’s tyrosine kinase inhibitor under evaluation as a monotherapy and in combination with other treatments for various B-cell malignancies.